pharmaand GmbH
22
0
1
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
18.2%
4 terminated/withdrawn out of 22 trials
81.0%
-5.6% vs industry average
23%
5 trials in Phase 3/4
82%
14 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Role: lead
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Role: lead
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Role: lead
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
Role: lead
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Role: lead
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Role: lead
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Role: lead
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
Role: lead
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Role: lead
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Role: lead
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Role: lead
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Role: lead
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
Role: lead
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
Role: lead
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Role: lead
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Role: lead
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Role: lead
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Role: lead
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Role: lead
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Role: lead